Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $1000.0.

  • Contineum Therapeutics' Amortizatization of Intangibles fell 9987.23% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 5683.77%. This contributed to the annual value of $3.9 million for FY2024, which is 4728.97% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Amortizatization of Intangibles stood at $1000.0, which was down 9987.23% from $407000.0 recorded in Q2 2025.
  • Contineum Therapeutics' Amortizatization of Intangibles' 5-year high stood at $1.2 million during Q4 2023, with a 5-year trough of $1000.0 in Q3 2025.
  • Its 3-year average for Amortizatization of Intangibles is $664363.6, with a median of $783000.0 in 2024.
  • As far as peak fluctuations go, Contineum Therapeutics' Amortizatization of Intangibles soared by 38812.79% in 2024, and later crashed by 9987.23% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Amortizatization of Intangibles stood at $1.2 million in 2023, then dropped by 11.1% to $1.1 million in 2024, then crashed by 99.91% to $1000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $1000.0 for Q3 2025, versus $407000.0 for Q2 2025 and $285000.0 for Q1 2025.